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Background: Partial nephrectomy (PN) preserves renal function and has become the standard approach for T1a
renal cell carcinoma (RCC). However, there is still an ongoing debate as to which patients will actually derive
greater benefit from partial than from radical nephrectomy (RN). The aim of this study was to retrospectively
evaluate the impact of the type of surgery on overall survival (OS) in patients with localized RCC.
Methods: Renal surgery was performed in 4326 patients with localized RCC (pT ≤ 3a N/M0) at six German tertiary
care centers from 1980 to 2010: RN in 2955 cases (68.3%), elective (ePN) in 1108 (25.6%), and imperative partial
nephrectomy (iPN) in 263 (6.1%) cases. The median follow-up for all patients was 63 months. Kaplan-Meier and Cox
regression analyses were carried out to identify prognosticators for OS.
Results: PN was performed significantly more often than RN in patients presenting with lower tumor stages, higher
RCC differentiation, and non-clear cell histology. Accordingly, the calculated 5 (10)-year OS rates were 90.0 (74.6)%
for ePN, 83.9 (57.5)% for iPN, and 81.2 (64.7)% for RN (p < 0.001). However, multivariate analysis including age, sex,
tumor diameter and differentiation, histological subtype, and the year of surgery showed that ePN compared to RN
still qualified as an independent factor for improved OS (HR 0.79, 95% CI 0.66-0.94, p = 0.008).
Conclusion: Even allowing for the weaknesses of this retrospective analysis, our multicenter study indicates that in
patients with localized RCC, PN appears to be associated with better OS than RN irrespective of age or tumor size.Background
Complete surgical excision of the tumor still remains the
only curative treatment for renal cell carcinoma (RCC)
[1]. Preserving renal function by performing partial neph-
rectomy (PN), was originally reserved for patients with an
anatomically or functionally solitary kidney or for those
with a functioning contralateral kidney at risk for future
functional impairment [2]. However, the use of PN has
increased tremendously, even in patients with localized
unilateral RCC and a healthy contralateral kidney [3].
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unless otherwise stated.equivalent to those of radical nephrectomy (RN) [4-7],
combined with limited perioperative morbidity [8], PN
has become the gold standard for all patients with renal
tumors < 4 cm [1,6,9,10]. Some authors recommend PN
in all cases where PN is oncologically safe and technically
feasible, even for pT ≥ 1b and high-risk tumors [10-13].
This is surely attributable in part to recent studies demon-
strating that elective PN (ePN) can be associated with sig-
nificantly lower long-term mortality than RN [14-17],
probably due to the preservation of renal function [18-20]
and the lower incidence of subsequent cardiovascular dis-
eases (CVD) [14].
While it is indisputable that PN leads to better preser-
vation of renal function, there is still debate over the
extent to which this surgically induced chronic kidneyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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related death [21-23]. This observation became a particu-
larly hot issue after van Poppel et al. [24] published the
overall survival (OS) results of the EORTC 30904 phase
III study. Contrary to expectations, the authors found no
OS advantage of ePN over RN.
In view of these contradictory results, this large retro-
spective multicenter study was performed to compara-
tively investigate partially and radically nephrectomized
patients comprising tumor and patient parameters and
to evaluate the influence of the surgical technique on
OS of patients with localized RCC.
Methods
Patient selection and tumor characteristics
This study included 4326 patients who underwent sur-
gery for localized RCC (pT1-3a, no detectable metas-
tasis at the time of surgery) between 1980 and 2010 at
Homburg (n = 1200), Mainz (n = 911), Hannover (n = 647;
1991–2005), Ulm (n = 495; 1998–2010), Jena (n = 597)
or Marburg (n = 476; 1990–2005) University Medical
Centers. Preoperative staging included CT scan in most
cases. Selection of patients for PN was based on tumor
size and location as well as on discussions and approval by
tumor boards at each center and/or the patient’s or sur-
geon’s preference. PN was defined as “imperative” in case
of significant preexisting renal insufficiency (GFR < 60 ml/
min) and/or the absence of a normal contralateral kidney.
However, eventually the definition of an “imperative” indi-
cation was based in every individual case on the personal
judgment of the operating surgeon.
Staging was based on the 2002 TNM classification sys-
tem. Institutional databases provided information on pa-
tient and tumor characteristics. The primary end point
of this study was OS. The ethics committees of each
institution (Ethics Committee of the Medical School
Hannover; Ulm University Medical Center; State Chamber
of Physicians Rheinland-Pfalz, Germany; Jena University
Hospital and State Chamber of Physicians Saarland) ap-
proved the study.
Statistical methods
Continuous variables were reported as mean values and
standard deviations (SD) for parametric distributions or
as median values and interquartile ranges (IQR) for non-
parametric distributions. Chi-square or Fisher’s exact tests
were conducted to assess differences in covariate distribu-
tions between patients treated by PN and those who under-
went RN. Kaplan-Meier estimates of survival time were
calculated, and subgroups were compared by the log rank
test. Multivariate Cox regression models were used to as-
sess the association between survival and the chosen sur-
gical procedure adjusted for different patient and tumor
covariates. SPSS 19.0 was used for statistical assessment.In all tests, a two-sided p < 0.05 was considered to indicate
significance.
Results
Our patient population of 2675 (61.8%) men and 1651
(38.2%) women had a mean (median) age of 61.2 (62.0)
years (range, 16–92). 3545 (81.9%) had clear cell, 496
(11.5%) papillary, 182 (4.2%) chromophobe, and 103
(2.3%) unclassified RCC. There were 3259 (75.3%) pa-
tients with pT1, 530 (12.3%) with pT2, and 537 (12.4%)
with pT3a RCC. The mean (median) tumor size was 4.9
(4.3) cm (SD ±2.7 cm).
The tumor grade was G1 in 1020 (24.5%), G2 in 2705
(65.0%), G3 in 420 (10.1%), and G4 in 16 (0.4%) of all
evaluable patients (Table 1). The mean (median) follow-up
for all patients was 74 (63) months (IQR: 30–109 months).
It did not differ significantly between patients treated
with RN (mean, 75 months) and elective PN (ePN; mean,
72 months, p = 0.07, t-test), but was shorter in those
who received an imperative PN (iPN; mean, 65 months,
p = 0.003, t-test). By the last day of data acquisition, 1061
(24.5%) had died of RCC or other causes.
Correlation of the surgical approach with patient/tumor
characteristics
ePN was performed in 1108 (25.6%), iPN in 263 (6.1%)
and RN in 2955 (68.3%) patients. Tumors were signifi-
cantly better differentiated and smaller in the PN than in
the RN subgroup (Table 1). Accordingly, patients with
early stage RCC were treated by PN significantly more
often than those with higher tumor stages (p < 0.001,
chi2 test, Table 1). Non-clear cell RCC was found more
frequently in patients submitted to ePN and iPN than in
those undergoing RN (Table 2). Interestingly, non-clear
cell tumors were not significantly smaller than clear cell
RCC (mean, 4.88 vs. 4.95 cm, p = 0.57, t-test). Among all
evaluable patients, 7.6% in the ePN, 16.1% in the iPN,
and 27.2% in the RN subgroup presented with clinical
symptoms at the time of diagnosis (p < 0.001, chi2 test).
Finally, patients who underwent ePN were significantly
younger than those submitted to RN (Table 1). Surpris-
ingly, more men than women (28.0% vs. 21.8%; p < 0.001,
chi2 test) were treated by ePN, even though the mean
tumor diameter did not differ significantly between men
and women (4.9 vs. 5.0 cm; p = 0.17, t-test) Table 2.
Association between tumor/patient characteristics, the
type of surgery, and overall survival
Using univariate Cox regression analysis we could reveal
that in contrast to male sex (HR 1.04, 95% CI 0.92-1.18,
p = 0.51) and non-clear cell histology (HR 0.93, 95% CI
0.79-1.10, p = 0.40), the following were significantly asso-
ciated with reduced OS: age (in years, HR 1.05, 95% CI
1.04-1.06, p < 0.001), tumor stage (p < 0.001), increasing
Table 1 Association between different patient and tumor parameters according to surgical procedure
Variable RN ePN iPN p-value Test
Age ± SD, mean [years]1 61.6 ± 11.1 59.7 ± 11.6 62.8 ± 11.2 < 0.001 ANOVA
Sex < 0.001 chi-square
Female 1186 (40.1%) 360 (32.5%) 105 (39.9%)
Male 1769 (59.9%) 748 (67.5%) 158 (60.1%)
Tumor diameter ± SD, mean [cm] 5.6 ± 2.7 3.4 ± 1.8 4.2 ± 2.2 < 0.001 ANOVA
Stage < 0.001 chi-square
pT1a 941 (31.8%) 859 (77.5%) 135 (51.3%)
pT1b 1033 (35.0%) 199 (18.0%) 92 (35.0%)
pT2 489 (16.5%) 26 (2.3%) 15 (5.7%)
pT3a 492 (16.6%) 24 (2.2%) 21 (8.0%)
Grade < 0.001 chi-square
G1/2 2468 (87.6%) 1024 (93.6%) 233 (93.6%)
G3/4 350 (12.4%) 70 (6.4%) 16 (6.4%)
Histological subtype < 0.001 chi-square
ccRCC 2492 (85.8%) 846 (76.6%) 207 (79.6%)
Non-ccRCC 411 (14.2%) 258 (23.4%) 53 (20.4%)
1At the time of renal surgery. Abbreviations: SD = standard deviation, RN = radical nephrectomy, ePN = elective partial nephrectomy, iPN = imperative partial
nephrectomy, RCC = renal cell carcinoma, RCC, ccRCC = clear cell RCC.
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and poor tumor differentiation (HR 2.10, 95% CI 1.76-
2.50, p < 0.001). The type of tumor surgery also correlated
significantly with OS: unlike iPN (HR 1.12, 95% CI 0.88-
1.43, p = 0.35), ePN was associated with a significantly
longer OS than RN (HR 0.61, 95% CI 0.51-0.71, p < 0.001).
The Kaplan-Meier 5- and 10-year OS rates were 90.0% andTable 2 Factors that influenced the type of surgery (ePN
vs. RN) in patients with pT ≤ 3a RCC and no detectable
metastasis at the time of surgery using multivariate
regression analysis
Variable P value OR (95% CI)










Tumor diameter [in cm] < 0.001 0.52 (0.49-0.56)
Medical center < 0.001
Time of surgery [in years] < 0.001 1.06 (1.04-1.08)
RCC = renal cell carcinoma, ccRCC = clear cell RCC, G = tumor grade, RN = radical
nephrectomy, ePN = elective partial nephrectomy, RN = radical nephrectomy.74.6% for ePN, and 81.2% and 64.7% for RN (p < 0.001; log
rank; Figure 1).
To further assess the potential advantage of ePN over RN,
we separately evaluated patients with tumors ≤ 4 and >
4 cm. In either case ePN was associated with significantly
improved OS (HR 0.68, 95% CI 0.55-0.85, p = 0.001 for
RCC ≤ 4 cm, and HR 0.69, 95% CI 0.51-0.93, p = 0.02 for
RCC > 4 cm; univariate Cox regression).
The impact of age was also taken into consideration.
A survival advantage of ePN over RN was found in all four
calculated age subgroups (< 55, 55–63, 63–69, and >
69 years): HR 0.52 (95% CI 0.35-0.78), HR 0.70 (95% CI
0.51-0.96), HR 0.58 (95% CI 0.40-0.83), and HR 0.71 (95%
CI 0.54-0.94; univariate Cox regression).
Finally, OS was superior with ePN vs. RN in all 5 periods
evaluated: < 1990: HR 0.80 (95% CI 0.57-1.12), 1990–1994:
HR 0.62 (95% CI 0.46-0.84), 1995–1999: HR 0.51 (95% CI
0.36-0.72), 2000–2004: HR 0.57 (95% CI 0.39-0.84), ≥ 2005:
HR 0.56 (95% CI 0.27-1.13).
Parameters affecting overall survival in multivariate
analysis
Multivariate analysis confirmed that in our population of
patients with pT ≤ 3a RCC and no detectable metastasis
at the time of renal surgery, the type of surgery was an
independent prognosticator for OS; ePN versus RN was
associated with a hazard ratio of 0.79 (95% CI 0.66-0.94,
p = 0.008, Cox regression; Table 3). We subsequently re-
peated our multivariate analysis with stepwise exclusion
of different medical centers to avoid a bias caused by
Figure 1 Overall survival (Kaplan-Meier) for patients with pT ≤ 3a RCC and no detectable metastasis at the time of surgery plotted
against the surgical procedure. The 5- and 10-year survival rates of all evaluable patients were 81.2% and 64.7% for RN (n = 2936), 90.0% and
74.6% for ePN (n = 1103), and 83.9% and 57.5% for iPN (n = 261) (p < 0.001, log rank).
Table 3 Multivariate analysis identified elective nephron-
sparing surgery (ePN) as an independent prognostic factor
for overall survival in patients with pT≤ 3a RCC and no
detectable metastasis at the time of surgery including all
participating centers
Variable P value HR (95% CI)










Tumor diameter [in cm] < 0.001 1.07 (1.04-1.09)
Surgical procedure 0.02
RN 1 (Reference)
ePN 0.008 0.79 (0.66-0.94)
iPN 0.62 1.07 (0.83-1.38)
Year of surgery [in years] 0.01 0.99 (0.98-0.99)
1At the time of surgery. RCC = renal cell carcinoma, ccRCC = clear cell RCC,
G = tumor grade, RN = radical nephrectomy, ePN = elective partial nephrectomy,
iPN = imperative partial nephrectomy.
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tio for ePN varied but was significantly < 1.0 (range: 0.61-
0.89) for all possible calculations.
Discussion
For many decades, RN was regarded as standard therapy
for localized RCC [25]. This dogma has changed dramatic-
ally in recent years [1] because a large number of studies
have shown that PN for elective or imperative indications
is a technically feasible and safe surgical procedure with
an only slightly higher complication rate [6,8,26]. More-
over, the oncological outcomes appear to be fully compar-
able in terms of local relapses and tumor-specific survival
[4,6,24]. The main advantage of PN, however, lies in
the markedly lower rate of postoperative renal failure
achieved by preserving functional nephrons [18,19,21,24].
Thus, nephron sparing surgery-especially ePN-is now con-
sidered the gold standard for treatment of small renal tu-
mors [1,9].
Several non-randomized studies have recently described
a longer OS for PN than for RN in patient populations
with mostly small renal tumors [14,15,27,28]. This was at-
tributed to lower rates of surgery-associated chronic renal
failure and subsequent CVD. However, these results do
not go unchallenged [21], and the studies largely show the
same limitations: retrospective and not comprehensive
data collection, mostly small patient populations, and
possible selection bias. Moreover, it has not yet been
fully clarified whether surgically induced renal failure,
like the type of chronic renal failure due to various
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CVD and subsequent mortality [22,29].
Up to now, there has been only one randomized phase
III study (EORTC-GU 30904) comparing the safety and
effectiveness of ePN and RN in patients with localized
renal tumors [24]. The 541 patients included had renal
tumors up to 5 cm in diameter. During a median follow-
up of more than 9 years, no survival advantage was
found for patients who underwent PN. On the contrary,
the intent-to-treat population had a calculated 10-year
OS rate of 81.1% for RN and only 75.7% for ePN, and
the PN group did not have fewer cardiovascular events
(9.3% vs. 7.3%). Tumor-specific survival was nearly
equal. Limitations of the study include the involvement
of 45 varyingly experienced centers in 17 countries and
the failure to recruit the intended sample size (1300 pa-
tients). Nevertheless, this randomized investigation was
unable to demonstrate a survival advantage for PN.
Since these results were generally surprising and did not
appear to be scientifically conclusive, we found it expedi-
ent to evaluate another very large patient population
that was treated at 6 German university medical centers.
Unlike the EORTC trial [24], our retrospective study
only included patients with histologically verified RCC.
Since those who underwent ePN in our patient popula-
tion had a younger median age as well as smaller and
better differentiated tumors, it was not surprising that
they had a significantly longer median OS than those
submitted to RN. However, subsequent multivariate ana-
lysis also showed a significant survival advantage for the
ePN group.
Even though we are dealing with a retrospective analysis
that does not include comorbidity, this large study shows
that OS appears to be better, but by no means worse, for
ePN than for RN. Of great interest is also the finding that
patients who underwent nephron-sparing surgery for im-
perative indications did not have a significantly worse
prognosis than the RN group, even though they probably
tended to have more serious comorbidities.
Therefore, our results are in line with a recent meta-
analysis published by Kim et al. [30] who also found that
PN lead to a 19% risk reduction in all-cause mortality.
However, in contrast to our study evaluating a rather
homogeneous patient collective with surgically resected
RCC, Kim et al. [30] included patients with benign tu-
mors and patients from observational studies.
Our results also support current recommendations to
perform a PN for small renal tumors. However, in line
with other recent publications [5,10-13,31], we were able
to demonstrate in subgroup analyses that PN may also
be justified for larger tumors leading to a potentially bet-
ter prognosis.
Hillyer et al. [32] recently described that even elderly RCC
patients do not have a significantly increased perioperativerisk if submitted to organ-sparing surgery and benefit ac-
cordingly from PN. Smaldone et al. [33] demonstrated a
survival advantage of PN over RN for patients up to age
85. Chang et al. [34] examined the secondary economic
impact of RN compared to PN on the U.S. health care sys-
tem. They came to the conclusion that PN is associated
with fewer follow-up costs than RN irrespective of age,
which also reflects the lower postoperative morbidity rate
in patients treated by PN. We divided our patient popula-
tion into 4 subgroups to assess the influence of age on the
prognostic relevance of the surgical procedure. No signifi-
cant difference was found between the subgroups: ePN
was associated with a lower risk of shorter OS irrespective
of age.
However, our study also has significant limitations. It
is a retrospective non-randomized study in which patients’
comorbidities and general condition could not be taken
into account. There was also a lack of detailed information
on preoperative renal function. Moreover, there was no
stringent standardization of criteria for the selection of the
surgical approach and no central pathological review.
Thus, a significant selection bias cannot be excluded. Only
recently, Shuch et al. [35] published a highly interesting
matched cohort study using the Surveillance, Epidemi-
ology, and End Results (SEER)-Medicare data base. Eld-
erly patients treated with PN or RN for localized RCC (≤
4 cm) were compared with two control groups (non–
muscle-invasive bladder cancer and noncancer controls).
Median overall survival following PN was significantly
higher than in controls without cancer or with nonmuscle
invasive bladder cancer, while median overall survival after
RN was similar among the 3 groups, confirming the hy-
pothesis that selection bias may be present in observa-
tional data and that RN may be less harmful than often
believed [35,36].
On the other hand, our study stands out in that we
could assess whether PN was performed for elective or
imperative indications even though this definition was
not based on hard criteria but the individual subjective
surgeon’s appraisal (based on the number of kidneys,
renal function and comorbidities). Remarkably, the iPN
group showed a poorer prognosis than the ePN group,
as expected, but not a significantly worse OS than the
RN group. At the same time, it can at least be speculated
that the patients submitted to iPN probably tended to
have the highest comorbidity in our patient population.
A last limitation is that a tumor-specific survival analysis
could not be performed for lack of reliable cause-of-death
information.
Taken together, our results suggest that PN is associ-
ated with a potentially better but apparently not worse
OS irrespective of center, age, and tumor size. This
could of course only be definitively confirmed by an ad-
equately large randomized study that provides detailed
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ties including renal function, and tumor-specific charac-
teristics; a valid nephrometry score might also be taken
into account [37-39]. However, it seems doubtful at
present whether such a study a) would achieve better pa-
tient recruitment than the already prematurely termi-
nated EORTC 30904 trial and b) would still be ethically
acceptable, at least for patients with small tumors. There
is also the question of what could possibly argue against
performing a PN, whether for elective or imperative in-
dications, considering that the rate and severity of post-
interventional chronic renal failure could be significantly
reduced, while perioperative morbidity is not signifi-
cantly increased, and oncological outcomes are compar-
able to those of RN. Is this alone not reason enough to
favor PN, regardless of whether or not the surgically in-
duced chronic renal failure is directly associated with
the occurrence of CVD? In any case, the results of our
large multicenter study support the performance of PN in
all cases where it appears technically feasible and oncolo-
gically safe.
Conclusion
Even allowing for the significant weaknesses and selec-
tion bias any retrospective analysis may involve, our re-
sults indicate that in patients with localized RCC, PN
may be associated with better OS than RN. Patients with
RCC > 4 cm as well as elderly patients did also seem to
benefit from a nephron-sparing approach.
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